Sanofi's lunsekimig meets goals in asthma, nasal polyps studies

April 7, 2026 1:01 AM

Sanofi (EURONEXT: SAN, NASDAQ: SNY) announced that its experimental drug lunsekimig achieved primary and key secondary endpoints in phase 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found